{
  "documents": [
    {
      "id": "cluster_5_doc1",
      "content": "A recent audit revealed inconsistencies in claim processing for patients enrolled in policy HNX-882K at Crestview Medical Center. Several cases involving immunotherapy treatments for rare conditions were flagged due to missing pre-authorization documentation. The audit report notes a particular case where a 43-year-old patient underwent IL-2 therapy without proper coding.",
      "metadata": {
        "format": "audit_report"
      }
    },
    {
      "id": "cluster_5_doc2",
      "content": "Provider report from Dr. Ellison at Crestview Medical Oncology details treatment protocol adjustments for patient ID#3971-882K-55. The patient's combination immunotherapy regimen was modified on 11/03/2023 due to elevated liver enzymes, transitioning from IL-2 to interferon-alpha treatment under research protocol ONC-2023-441.",
      "metadata": {
        "format": "provider_report"
      }
    },
    {
      "id": "cluster_5_doc3",
      "content": "Crestview Tribune article highlights increased insurance denials for advanced therapies since policy HNX-882K implementation. The piece interviews a patient quoted as saying 'My immunotherapy was denied three times despite meeting criteria,' and references ongoing research studies at the medical center's oncology wing.",
      "metadata": {
        "format": "news_article"
      }
    },
    {
      "id": "cluster_5_doc4",
      "content": "Memo from insurance underwriters details new documentation requirements for policy HNX-882K effective 01/15/2024. All immunotherapy claims must now include liver function panel results and biopsy confirmation of disease progression from within 60 days prior to treatment initiation.",
      "metadata": {
        "format": "insurance_memo"
      }
    },
    {
      "id": "cluster_5_doc5",
      "content": "Patient satisfaction survey submitted by participant in research study ONC-2023-441 reports difficulties navigating prior authorization process for medications. The respondent listed contact attempts through both 800-555-0199 and provider's direct line at 212-555-0167 before receiving approval.",
      "metadata": {
        "format": "patient_survey"
      }
    },
    {
      "id": "cluster_5_doc6",
      "content": "Research note from Crestview Medical Center indicates that 68% of patients on policy HNX-882K receiving IL-2 therapy required treatment modifications within first three cycles. Secondary analysis shows improved tolerance in patients transitioning to interferon-alpha regimens as per study ONC-2023-441 protocols.",
      "metadata": {
        "format": "research_note"
      }
    }
  ],
  "metadata": {
    "category": "cluster",
    "cluster_id": "cluster_5",
    "cluster_risk": "MEDIUM",
    "content_summary": "A patient's journey through immunotherapy treatment at Crestview Medical under policy HNX-882K, including treatment modifications, insurance challenges, and research study participation.",
    "person": {
      "entities": [
        [
          "HNX-882K",
          "NON_PERSONAL_ID"
        ],
        [
          "3971-882K-55",
          "PATIENT_ID"
        ],
        [
          "43-year-old",
          "AGE"
        ],
        [
          "IL-2 therapy",
          "TREATMENT"
        ],
        [
          "interferon-alpha treatment",
          "TREATMENT"
        ],
        [
          "ONC-2023-441",
          "NON_PERSONAL_ID"
        ],
        [
          "Crestview Medical Center",
          "LOCATION"
        ],
        [
          "Dr. Ellison",
          "PROVIDER"
        ],
        [
          "11/03/2023",
          "EVENT_DATE"
        ]
      ]
    },
    "questions": [
      {
        "q": "Which two immunotherapy treatments did patient ID#3971-882K-55 receive under research protocol ONC-2023-441 at Crestview Medical?",
        "a": "IL-2 therapy followed by interferon-alpha treatment",
        "sources": [
          "cluster_5_doc2"
        ],
        "type": "specific"
      },
      {
        "q": "What new documentation requirements were added to policy HNX-882K effective January 2024?",
        "a": "Liver function panels and recent biopsy confirmation",
        "sources": [
          "cluster_5_doc4"
        ],
        "type": "general"
      },
      {
        "q": "Based on the audit report and provider report, what is the patient’s age and what treatment change was made due to elevated liver enzymes?",
        "a": "43-year-old; switched from IL-2 to interferon‑alpha because of elevated liver enzymes.",
        "sources": [
          "cluster_5_doc1",
          "cluster_5_doc2"
        ],
        "type": "specific"
      },
      {
        "q": "What percentage of HNX-882K patients needed IL-2 therapy modifications within three cycles, and which research protocol described the typical modification?",
        "a": "68%; protocol ONC-2023-441.",
        "sources": [
          "cluster_5_doc6",
          "cluster_5_doc2"
        ],
        "type": "general"
      }
    ]
  }
}